DIACEUTICS PLC

Director's Dealing • May 5, 2020

National Storage Mechanism | Additional information

RNS Number : 9755L

Diaceutics PLC

05 May 2020

Diaceutics PLC

("Diaceutics" or the "Company")

5 May 2020

Director's Shareholding - PCA Dealing

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces that Delia Keeling, wife of Peter Keeling, Chief Executive of Diaceutics, has transferred a total of 24,000 ordinary shares in the Company held by her to certain members of her family for nil consideration. The transfers were effected on 21 April 2020.

The following additional information is disclosed in accordance with article 19(3) of the Market Abuse Regulation.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Delia Keeling
2	Reason for notification
a.	Position/Status	Wife of Peter Keeling, Chief Executive Officer of Diaceutics plc
b.	Initial notification/ Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Diaceutics plc
b.	LEI	213800VEWQBB39ZB8J81
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of 0.2p each ISIN:  GB00BJQTGV64
b.	Nature of the transaction	Transfer of shares to certain family members for nil consideration. The transfer comprised 1,000 shares each transferred to 24 individuals, all for nil consideration.
c.	Price(s) and volume(s)
	Price(s)	Volume(s)
Nil	24,000
e.	Date of the transaction	21 April 2020
f.	Place of the transaction	Outside a trading venue

Enquiries:

Diaceutics PLC	www.diaceutics.com
Peter Keeling, Chief Executive Officer	via Walbrook PR
Philip White, Chief Financial Officer
Cenkos Securities plc (Nominated adviser and broker)			+44 (0) 20 7391 8900
Callum Davidson / Giles Balleny
Michael Johnson (Sales)
Walbrook PR	Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com
Anna Dunphy		Mob: +44 (0)7876 741 001
Paul McManus		Mob: +44 (0)7980 541 893

About Diaceutics

Diaceutics PLC is the diagnostic commercialisation company for global pharmaceutical companies. The Company, quoted on the Alternative Investment Market (AIM) of the London Stock Exchange, is enabling pharma to accelerate their market penetration and achieve a better return on precision medicine therapies by helping them to revolutionise patient testing.  By generating insights from its data lake of clinical laboratory testing data and other data, Diaceutics helps pharma understand and leverage the diagnostic landscape through initiatives that improve patient testing, leading to better treatment outcomes. The Company works with more than 35 global pharmaceutical companies across hundreds of precision medicine projects. The Company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries.  www.diaceutics.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHSSUFSIESSEFI